Everest Acquires Global Rights to Protease Inhibitor Therapies for COVID-19

Everest Medicines acquired global rights to several early stage protease inhibitor candidates for SAR-CoV-2 from S ingapore 's Experimental Drug Development Centre.  Everest will have exclusive rights to develop, sub-license and commercialize EDDC's series of viral 3C-like protease inhibitors as COVID-19 oral antiviral treatments. The candidates have shown potent in-vitro activity against SAR-CoV-2 and its variants, as well as other coronaviruses such as MERS. Clinical trials of the lead candidate are expected to begin later this year. Financial details of the transaction were not disclosed. More details.... Stock Symbol: (HK: 1952) Share this with colleagues: // //